Clinical-stage biotech developing novel precision psychiatric medicines targeting brain plasticity mechanisms for depression, anxiety, and addiction.
Gilgamesh Pharmaceuticals is a clinical-stage biotechnology company developing novel chemical entities (NCEs) that engage brain plasticity mechanisms to treat psychiatric conditions including depression, anxiety, addiction, and schizophrenia. Its pipeline includes Bretisilocin (GM-2505, acquired by AbbVie), Blixeprodil (GM-1020, an oral NMDAR antagonist), Neuroplastogens (in partnership with AbbVie), GM-3009 (ibogaine analogs for opioid use disorder), and an M1/M4 agonist for schizophrenia. Discovery is powered by a platform combining medicinal chemistry with AI-driven translational methods. Gilgamesh Pharmaceuticals is a product of Gilgamesh Pharmaceuticals.